In addition, higher levels of NLRP3 and caspase-1 were observed in patients with rheumatoid arthritis than in patients with degenerative arthritis, and it was found that the administration of selective NLRP3 inhibitors reduced redness and cartilage degradation [57]. This evidence concerns the gene CASP1 and osteoarthritis.